Fagron NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
02 aug 2013 - 07:50
Statutaire naam
Fagron NV
Titel
Innovation strategy results in strong increase of gross margin and profitability
Bericht
EBIT increases 45.4% at turnover growth of 5.4%
Key points of the first half of 2013:
• Turnover increased by 5.4% to € 282.7 million
• Organic growth at constant exchange rates was 5.9%
• REBITDA increased by 29.9% to € 50.4 million
• EBITDA increased by 34.7% to € 44.2 million
• EBIT increased by 45.4% to € 35.6 million
• Net profit increased by 23.0% to € 18.8 million
• Outlook for 2013: Healthy organic turnover growth and profitability that grows faster than turnover
Ger van Jeveren, CEO of Arseus: "The results of Arseus for the first six months of 2013 are excellent. Turnover increased by 5.4% to € 282.7 million. Organic turnover growth at constant exchange rates of Arseus was 7.7% in the second quarter of 2013. Consistent optimisation of the product portfolio has resulted in an increase of Arseus' gross margin by no less than 2.9 percentage points in the first six months of 2013 compared with the same period in 2012. All divisions contributed to this increase. Operational excellence and a closely monitored cost policy resulted in a substantial decrease in operating costs as a percentage of turnover. The significant turnover growth, strong increase in the gross margin and lower costs resulted in an impressive increase in the REBITDA, EBITDA, EBIT and net profit. For 2013, we expect healthy organic growth and profitability that grows faster than turnover. We look to the future with great confidence.
The Board of Directors of Arseus recently started an analysis of strategic options, both inside and outside Arseus, for the Healthcare Solutions and Healthcare Specialties divisions. After concluding this analysis, the Board of Directors will announce the results in a press release."
Datum laatste update: 13 november 2024